Navigation Links
Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop

/ II Trial of VELCADE and Perifosine (KRX-0401) in Relapsed / Refractory Multiple Myeloma Patients Previously Treated with VELCADE: Preliminary Results * Lead investigator: Paul Richardson, M.D., Dana-Farber Cancer Institute * Abstract #608; Poster session: Thursday 28th June, 4:30 p.m. -- Combination of the mTOR-Inhibitor Rapamycin and Proteasome Inhibitor VELCADE is Synergistic In Vitro in Multiple Myeloma * Lead investigator: Xavier Leleu, M.D., Centre Hospitalier Regional Universitaire de Lille * Abstract #534; Poster session: Tuesday 26th June, 4:30 p.m.

About Multiple Myeloma (MM)

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and close to 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and more than 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is c
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 26, 2011 NuMe Health LLC, a biotechnology company ... today announced that it has closed a series A-1 ... chief executive officer.  The $675,000 financing was led by ... a larger series A round. The funds from the ...
... 2011 Reportlinker.com announces that a new ... catalogue: China Cardiac Catheters ... http://www.reportlinker.com/p0575380/China-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital market data ...
Cached Medicine Technology:NuMe Health Announces Closing of Series A-1 Financing Round 2NuMe Health Announces Closing of Series A-1 Financing Round 3NuMe Health Announces Closing of Series A-1 Financing Round 4NuMe Health Announces Closing of Series A-1 Financing Round 5China Cardiac Catheters and Guidewires - Market Trends Till 2016 2China Cardiac Catheters and Guidewires - Market Trends Till 2016 3
(Date:10/1/2014)... ST. LOUIS, MO (PRWEB) October 01, 2014 ... up for Castlewood Eating Disorder Treatment Center’s first ever charity ... provides grants for people with eating disorders who cannot afford ... Fox Run Golf Club in Eureka, Mo. , The ... time at noon. A reception and award dinner will begin ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new ... and 13.0. NoteSwift is the bridge between the EHR ... and document clinical information at the point of care. ... patient note by more than half – and virtually ... points providers state impedes EHR use according to the ...
(Date:10/1/2014)... Scientists at the University of Western ... immune system proteins has the power to knock out ... of the new study on their website. Click ... in the UWA School of Pathology and Laboratory Medicine ... with mesothelioma with promising results. , “A timed ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... 5, 2008--Worldwide, an average 95.4 percent of LASIK patients ... first review of the world body of scientific literature, ... announced today. , With 16.3 million patients having ... clinical study and technological innovation behind it, LASIK is ...
... March 7 The rheumatoid arthritis (RA),treatment market, held ... withdrawal of Vioxx and Bextra, is rebounding due to ... to,treat RA topped $12 billion in 2006 and -- ... over 11% a year through 2011,according to a new ...
... Following Bi-Partisan Senate Letter, asks Lawmakers,to Reject Proposed ... Make,Reform Much More Difficult to Achieve, Letter ... WASHINGTON, March 7 The Council for Quality,Respiratory ... leading home oxygen,therapy providers and manufacturers who provide ...
... chief of developmental neurobiology at the Medical College of ... has received the 2008 Mathilde Solowey Lecture Award in ... for Advanced Education in the Sciences, honors young or ... edge, translational and of broad importance. , Dr. Mei ...
... generated by ... physicians in SEMI program, DETROIT, March 7 ... 2.5 million electronic prescriptions written in,the state of Michigan in 2007 ... Initiative (SEMI) -- helping drive,Michigan to fifth in the nation in ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a ... be exhibiting its AspirinWorks(R) Test at the,American College ... 2008 conference is being held March 12-14 at ... will be on-hand at booth #807 during ACOFP ...
Cached Medicine News:Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 2Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 3Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 4Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 3Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 2Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 2Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 4Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 5Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 6Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 2Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 3
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
... inhalers., ,ACE ensures prompt, effective delivery ... versatile design allows it to be used ... an endotracheal airway or resuscitation bag and ... be used in conjunction with an incentive ...
... can be held at angles up to 45° ... in spill column, finger grooves for a non-slip ... 7 feet of regular oxygen tubing. The ... size and sustain optimum mist concentration at every ...
Medicine Products: